RE:Moving on The difference between TH1902 and TH1904 is the payload, nothing else. Yes, Thera initially used TH1904 (doxorubicin payload) to for the preclinical ovarian cancer work. But then they used TH1902 (docetaxol payload) and found it actually worked better on ovarian cancer. than TH1904.
Sortilin receptor seems to be higher expressed as the disease gets to a later stage and the higher the grade is. There are 4 major subtypes in ovarian cancer but most (70%) are High Grade Serous ovarian cancer, which is the most malignant. And most are diagnosed at a later stage (III or IV). The hope in the study below was that if the cancer was diagnosed in an earlier stage then more women could be cured or survive longer.
From the approximately 20,000 women diagnosed with Ovarian cancer in the United States each year more than 70% will die within 5 years and 95% within 10 years. I believe if TH1902 works then these women are the candidates for TH1902. These would be the women most likely to have overexpressed sortilin receptor.
We are very early still. One of my questions is would it be possible to use TH1902 as a maintance treatment? To keep the cancer under control indefinetely?
As for possible cost. My wife had another re-occurence in December 2020. The oncologists didn't think that platinum based chemo would help much but to everyone's surprise she has responded well. So, the oncologist has recommended a parp inhibitor maintenance which could increase PFS by a few months. The cost of this treatment is about $11,000 per month (not covered by OHIP). If TH1902 can keep cancer patients (not just ovarian cancer) alive and be used as a maintenance treatment how much would that add up to?
scarlet1967 wrote: Ovarian cancer: Setback as major screening trial fails to save lives
Ovarian cancer: Setback as major screening trial fails to save lives
TH1904 seems to be targeting ovarian cancer as per google,:
“The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.”